Cutler Group’s Seres Therapeutics MCRB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q4
Sell
-311
Closed -$14K 4041
2023
Q3
$14K Sell
311
-4
-1% -$305 ﹤0.01% 2285
2023
Q2
$30K Buy
315
+125
+66% +$13.6K ﹤0.01% 1604
2023
Q1
$21K Sell
190
-5
-3% -$541 ﹤0.01% 1896
2022
Q4
$21K Hold
195
﹤0.01% 2186
2022
Q3
$25K Hold
195
﹤0.01% 2438
2022
Q2
$13K Hold
195
﹤0.01% 3014
2022
Q1
$27K Sell
195
-115
-37% -$17.7K ﹤0.01% 2793
2021
Q4
$51K Sell
310
-88
-22% -$14K ﹤0.01% 2391
2021
Q3
$55K Buy
398
+238
+149% +$46.6K ﹤0.01% 2434
2021
Q2
$76K Buy
160
+115
+256% +$48.5K ﹤0.01% 2118
2021
Q1
$18K Hold
45
﹤0.01% 3301
2020
Q4
$22K Sell
45
-284
-86% -$166K ﹤0.01% 2622
2020
Q3
$186K Sell
329
-201
-38% -$66.8K 0.01% 945
2020
Q2
$50K Hold
530
﹤0.01% 1749
2020
Q1
$37K Hold
530
﹤0.01% 1909
2019
Q4
$36K Hold
530
﹤0.01% 1858
2019
Q3
$42K Hold
530
﹤0.01% 1671
2019
Q2
$34K Hold
530
﹤0.01% 1829
2019
Q1
$72K Buy
530
+11
+2% +$1.34K 0.01% 1202
2018
Q4
$46K Hold
519
﹤0.01% 1527
2018
Q3
$78K Hold
519
0.01% 1339
2018
Q2
$89K Sell
519
-50
-9% -$8.17K 0.01% 1223
2018
Q1
$83K Hold
569
0.01% 1319
2017
Q4
$115K Buy
569
+45
+9% +$9.24K ﹤0.01% 1286
2017
Q3
$168K Sell
524
-216
-29% -$59K 0.01% 1288
2017
Q2
$167K Sell
740
-20
-3% -$4.11K 0.01% 1428
2017
Q1
$171K Buy
760
+10
+1% +$2.03K 0.01% 1307
2016
Q4
$148K Buy
750
+683
+1,019% +$149K 0.01% 1565
2016
Q3
$16K Buy
+67
New +$23.5K ﹤0.01% 3658
2016
Q2
Sell
-197
Closed -$116K 7011
2016
Q1
$104K Buy
+197
New +$103K 0.01% 1568

Other funds holding MCRB

Cutler Group's MCRB Position: Q4 2023 in Review

Cutler Group sold out of Seres Therapeutics (MCRB) in Q4 2023, closing a stake of 311 shares — an estimated $14K sold.

Cutler Group first reported a position in MCRB in Q1 2016 and held it in 30 quarters. The position peaked at $186K in Q3 2020. 102 funds tracked by Wall St. Rank hold MCRB as of Q4 2023.

  • Cutler Group reported no remaining Seres Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Cutler Group sold 311 Seres Therapeutics shares in Q4 2023, an estimated $14K.
  • Cutler Group first reported a position in Seres Therapeutics in Q1 2016 and held it in 30 quarters.
  • Cutler Group's Seres Therapeutics position peaked at $186K in Q3 2020.
  • 102 funds tracked by Wall St. Rank held Seres Therapeutics as of Q4 2023.

Based on Cutler Group's 13F filing for Q4 2023, filed 18 Jan 2024.